Talazoparib with enzalutamide for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This expanded access program provides the experimental drug talazoparib (given in combination with enzalutamide) to patients with newly diagnosed metastatic prostate cancer that has become castrate-resistant (no longer responding to hormone therapy). The goal is to make this treatment available before it is formally approved.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced prostate cancer that has spread to other parts of the body and is no longer controlled by testosterone-lowering therapy.
- You must not have started any first-line treatment for this stage of cancer yet. (Prior use of older-generation hormone pills, such as abiraterone, may be okay.)
- You cannot have taken any of these drugs before for any prostate cancer: enzalutamide, apalutamide, darolutamide, PARP inhibitors (like olaparib), cyclophosphamide, or mitoxantrone.
- You may have taken abiraterone or docetaxel if it was given before the cancer became castrate-resistant.
- You must not be taking certain drugs (like rifampin, carbamazepine, phenytoin, or St. John's Wort) that could interact with the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines radiation therapy with two drugs (fluzopanib and abiraterone acetate) to treat men with metastatic castration-resistant prostate cancer that hasn't been treated yet. The goal is to see if this triple approach helps slow the cancer's growth.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
This trial tests a combination of two drugs, talazoparib and enzalutamide, in men with advanced prostate cancer that has progressed after previous treatment with a hormone therapy called an AR inhibitor. It aims to see if this combination can help control the cancer and delay further progression.
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
This trial studies whether taking talazoparib and enzalutamide before surgery can shrink or control prostate cancer. If treatment works, it may make the cancer easier to remove with a radical prostatectomy.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.